Exact Sciences' stock rises as company anticipates $455M in 2018 revenue

Exact Sciences Corp., the Madison manufacturer of the Cologuard take-home colon cancer test, saw its stock rise sharply in early-morning trading Monday after the company posted estimations for its recent fourth quarter and full-year 2018 revenue. The company's fourth-quarter sales would range between $142.5 million and $143.5 million, the company said in a news release, which would be an increase of 64 percent when compared with the same quarter of 2017. For its full year 2018 results, Exact Sciences…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news